Quick Takeaways Why It Matters? Gelteq’s animal health trial gives it a foothold in the large antiparasitic market and turns its gel-based platform into a potential formulation partner for veterinary pharma, not just nutraceuticals. If the data support a later FDA filing,...
Quick Takeaways Why It Matters? CosACTHen gives Dechra a differentiated diagnostic anchor in canine endocrinology and should strengthen its existing Cushing’s/Addison’s franchise built around Vetoryl. As the first and only FDA‑approved cosyntropin spec...
Quick Takeaways Why It Matters? This deal gives Viromed a faster route to commercialize PulmoPlas in veterinary respiratory care, starting with horses, while NEBU-TEC gets exclusive global distribution rights in that segment. The biggest market upside is in ...
Quick Takeaways Why It Matters? Piclidenoson could open a new, higher‑value segment in the canine osteoarthritis market as one of the first oral, potentially disease‑modifying options rather than just another pain reliever. If the ongoing Phase II trial confirms the posit...
Quick Takeaways Why It Matters? Liavium-CA1 gives Pegasus (PRN Pharmacal) a first-in-class, branded neurology asset in a completely underserved niche, which should support premium pricing and strong loyalty among neurologists and specialty practices that see CM/SM dogs. B...
Quick Takeaways Why It Matters? Befrena gives Elanco a direct challenger to Zoetis’ Cytopoint in the fast‑growing canine allergy biologics market, with a slightly longer recommended dosing interval (every 6–8 weeks vs 4–8 weeks) and no age or weight limits...
Quick Takeaways Why It Matters? VetSnap’s new 2‑Bay Smart Locker gives small and mobile veterinary practices a lower-cost way to get DEA‑compliant, automated storage and tracking for controlled drugs, instead of relying on basic safes and paper logs. By pricing...
Quick Takeaways Why It Matters? This Petco rollout gives Fera Pets a much bigger retail stage and moves its vet-founded, “clean-label” supplements from niche online channels into mainstream, in‑store traffic. This move will raise competitive pressure on legacy suppl...
Quick Takeaways Why It Matters? A new proprietary CNS asset from Orion, exclusively commercialized by Zoetis in the US, that taps into fast‑growing demand for medical management of canine anxiety and should expand the addressable market beyond situational noise phobia toward mo...
Quick Takeaways Why It Matters? Ceva is using this JV to turn Japan from a peripheral presence into a true platform market, bolting its global livestock and pet portfolio onto Bussan Animal Health’s 75‑year brand, field force, and ~€40M business to create a full‑line ...
